Healthcare Industry News:  thrombosis 

Devices Interventional Cardiology

 News Release - January 27, 2009

New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

BALTIMORE, Jan. 27 -- (Healthcare Sales & Marketing Network) -- Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for thrombosis Research based at Sinai Hospital of Baltimore, indicate that platelet aggregation or "stickiness" may be the single largest factor in determining the likelihood of developing serious complications, including heart attack, in patients treated with coronary artery stents.

"We currently measure the cholesterol level in everyone with vascular disease, yet the pivotal event that kills the patient - platelet aggregation isn't being assessed in any way," said Dr. Gurbel.

Dr. Gurbel's findings may explain why someone with no cardiac history could die suddenly of a massive heart attack, while an individual with high blood pressure, high cholesterol and plaque-filled arteries may never have a cardiac event because they had low platelet aggregation.

Along with his team at Sinai, Dr. Gurbel demonstrated that patients with platelets most prone to aggregate had the highest prevalence of complications, including heart attack, after coronary artery stenting.

Their work is helping to revolutionize the testing and treatment of patients with coronary artery disease, offering further evidence that a more personalized approach to anti-platelet therapy needs to be established.

Dr. Gurbel was one of the first researchers in the world to discover that up to 30% of patients taking clopidogrel, a drug designed to decrease platelet aggregation, do not respond to treatment.

"Of the millions of cardiac patients treated with clopidogrel, a significant percentage are non-responsive and remain at high risk for a major cardiac event," said Dr. Gurbel. "The platelet aggregation of each patient needs to be precisely measured to determine how well the drug is working. The blind administration of anti-platelet drugs without confirming a good response, in our opinion, will soon be reaching an end."

Visit this url for a recent story on Dr. Gurbel's research - http://www.wbaltv.com/video/17929792/index.html

About Sinai Hospital of Baltimore

Sinai Hospital of Baltimore is part of LifeBridge Health, a regional health organization that also includes Northwest Hospital, Levindale Hebrew Geriatric Center and Hospital, Jewish Convalescent & Nursing Home, and related subsidiaries and affiliates.


Source: Sinai Hospital of Baltimore

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.